Form 4 for BSX Boston Scientific
Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-15 · accession 0001225208-22-002669 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-17 | 2022-02-07 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | G - Gift | $0.00 | -2,780 | 207.8K | -1% | $0 |
| DI | 2022-02-17 | 2022-02-07 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | G - Gift | $0.00 | +1,390 | 7,428 | +23% | $0 |
| D | 2022-02-17 | 2022-02-15 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | F - Tax | $44.01 | -2,278 | 210.1K | -1% | -$100.3K |
| D | 2022-02-17 | 2022-02-15 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | M - OptEx | $0.00 | +4,614 | 212.4K | +2% | $0 |
| D | 2022-02-17 | 2022-02-15 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | M - OptEx | $0.00 | -4,614 | 4,615 | -50% | $0 |
| DM | 2022-02-17 | 2022-02-16 | BSX | Fitzgerald Joseph Michael | EVP, Pres, Cardiology | A - Grant | $0.00 | +61.1K | 15.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-07 | G | D | 2,780 | $0.00 | 207,752 | D By Children | — | — | |
| 2 | Common | Common Stock | 2022-02-07 | G | A | 1,390 | $0.00 | 7,428 | I | — | — | (F3) The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose. |
| 3 | Common | Common Stock | 2022-02-15 | F | D | 2,278 | $44.01 | 210,088 | D | — | — | |
| 4 | Common | Common Stock | 2022-02-15 | M | A | 4,614 | $0.00 | 212,366 | D | — | — | (F2) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 5 | Derivative | Deferred Stock Units | 2022-02-15 | M | D | 4,614 | $0.00 | 4,615 | D | — · — to 2023-02-15 | 4,614 Common Stock | (F2) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F5) Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-02-16 | A | A | 45,294 | $0.00 | 45,294 | D | $44.19 · — to 2032-02-16 | 45,294 Common Stock | (F8) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| 7 | Derivative | Restricted Stock Units | 2022-02-16 | A | A | 15,840 | $0.00 | 15,840 | D | — · — to 2026-02-16 | 15,840 Common Stock | (F6) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F7) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |